ATE551997T1 - Sulfonamid-derivate zur behandlung von diabetes - Google Patents
Sulfonamid-derivate zur behandlung von diabetesInfo
- Publication number
- ATE551997T1 ATE551997T1 AT04787131T AT04787131T ATE551997T1 AT E551997 T1 ATE551997 T1 AT E551997T1 AT 04787131 T AT04787131 T AT 04787131T AT 04787131 T AT04787131 T AT 04787131T AT E551997 T1 ATE551997 T1 AT E551997T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- sulfonamide
- treatment
- hydrogen
- nitrogen atom
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 3
- 150000003456 sulfonamides Chemical class 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- -1 amino, sulfanyl Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000003863 ammonium salts Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03102742 | 2003-09-12 | ||
| PCT/EP2004/052143 WO2005025558A1 (en) | 2003-09-12 | 2004-09-13 | Sulfonamide derivatives for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551997T1 true ATE551997T1 (de) | 2012-04-15 |
Family
ID=34306923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04787131T ATE551997T1 (de) | 2003-09-12 | 2004-09-13 | Sulfonamid-derivate zur behandlung von diabetes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7705052B2 (de) |
| EP (1) | EP1663193B1 (de) |
| JP (1) | JP4870562B2 (de) |
| AT (1) | ATE551997T1 (de) |
| AU (1) | AU2004271741A1 (de) |
| CA (1) | CA2534312A1 (de) |
| ES (1) | ES2385219T3 (de) |
| IL (1) | IL174251A0 (de) |
| NO (1) | NO20061598L (de) |
| WO (1) | WO2005025558A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4414219B2 (ja) * | 2001-07-23 | 2010-02-10 | メルク セローノ ソシエテ アノニム | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）インヒビターとしてのアリールスルホンアミド誘導体 |
| ATE551997T1 (de) | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
| AU2011265521B8 (en) * | 2005-07-15 | 2014-05-22 | Merck Serono Sa | JNK inhibitors for the treatment of endometreosis |
| BRPI0520579B8 (pt) * | 2005-08-12 | 2021-05-25 | Suven Life Sciences Ltd | composto, processo para a preparação de um composto e composição farmacêutica |
| JP5301465B2 (ja) | 2007-01-25 | 2013-09-25 | バーバ・ファーマシューティカルズ・リミテッド | インスリン抵抗性改善薬および治療方法 |
| US8507746B2 (en) * | 2008-12-16 | 2013-08-13 | Kimberly-Clark Worldwide, Inc. | Leakage-signaling absorbent article |
| US8225729B2 (en) * | 2008-12-16 | 2012-07-24 | Kimberly-Clark Worldwide, Inc. | Three-dimensional wiping substrate and method therefor |
| US8882735B2 (en) * | 2008-12-16 | 2014-11-11 | Kimberly-Clark Worldwide, Inc. | Article with fluid-activated barriers |
| US7858055B2 (en) * | 2008-12-18 | 2010-12-28 | Kimberly-Clark Worldwide, Inc. | Moisture sensitive auxetic material |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (de) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituierte heteroaryl- und arylcyclopropylaminacetamide und ihre verwendung |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| WO2011153359A1 (en) * | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| JP2013536233A (ja) * | 2010-08-23 | 2013-09-19 | アムジエン・インコーポレーテツド | グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物 |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| US8708988B2 (en) | 2010-12-03 | 2014-04-29 | Kimberly-Clark Worldwide, Inc. | Absorbent article configured for controlled deformation |
| EP2712315B1 (de) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysindemethylase-hemmer für myeloproliferative erkrankungen |
| EP2768805B1 (de) * | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamin verbindungen als lsd1 hemmer |
| JP6046154B2 (ja) | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ． アー． | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| JP6540505B2 (ja) * | 2013-03-29 | 2019-07-10 | 国立大学法人 熊本大学 | ２型糖尿病治療剤 |
| JP6602779B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3105218B1 (de) * | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamine als lsd1-hemmer |
| EP3105219B9 (de) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamine als lsd1-hemmer |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| EA039196B1 (ru) * | 2014-10-08 | 2021-12-16 | Инсайт Корпорейшн | Циклопропиламины в качестве ингибиторов lsd1 |
| EP3277689B1 (de) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclische verbindungen als lsd1-hemmer |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| TWI833686B (zh) | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| US10683292B2 (en) * | 2016-07-25 | 2020-06-16 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN119462614B (zh) * | 2025-01-14 | 2025-05-02 | 吉林大学 | 1-mhmd、制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
| US4927831A (en) | 1988-10-20 | 1990-05-22 | American Home Products | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors |
| CZ302691B6 (cs) * | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| EP1088821A1 (de) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksamer Sulfonamid Derivate |
| EP1088815A1 (de) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate |
| EP1193267A1 (de) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksame hydrophile Sulfonamidderivate zur Verwendung als Proteinjunkinasehemmer |
| EP1193256A1 (de) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch aktive Benzolsulfonamidderivate als JNK-Proteininhibitoren |
| EP1193268A1 (de) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen |
| WO2002100396A1 (en) | 2001-06-07 | 2002-12-19 | Wyeth | COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT |
| JP4414219B2 (ja) * | 2001-07-23 | 2010-02-10 | メルク セローノ ソシエテ アノニム | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）インヒビターとしてのアリールスルホンアミド誘導体 |
| ATE551997T1 (de) | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
-
2004
- 2004-09-13 AT AT04787131T patent/ATE551997T1/de active
- 2004-09-13 EP EP04787131A patent/EP1663193B1/de not_active Expired - Lifetime
- 2004-09-13 JP JP2006525836A patent/JP4870562B2/ja not_active Expired - Fee Related
- 2004-09-13 CA CA002534312A patent/CA2534312A1/en not_active Abandoned
- 2004-09-13 ES ES04787131T patent/ES2385219T3/es not_active Expired - Lifetime
- 2004-09-13 US US10/571,466 patent/US7705052B2/en not_active Expired - Fee Related
- 2004-09-13 WO PCT/EP2004/052143 patent/WO2005025558A1/en not_active Ceased
- 2004-09-13 AU AU2004271741A patent/AU2004271741A1/en not_active Abandoned
-
2006
- 2006-03-12 IL IL174251A patent/IL174251A0/en unknown
- 2006-04-07 NO NO20061598A patent/NO20061598L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004271741A1 (en) | 2005-03-24 |
| NO20061598L (no) | 2006-06-09 |
| EP1663193B1 (de) | 2012-04-04 |
| JP4870562B2 (ja) | 2012-02-08 |
| WO2005025558A1 (en) | 2005-03-24 |
| JP2007505088A (ja) | 2007-03-08 |
| IL174251A0 (en) | 2006-08-01 |
| CA2534312A1 (en) | 2005-03-24 |
| EP1663193A1 (de) | 2006-06-07 |
| US7705052B2 (en) | 2010-04-27 |
| ES2385219T3 (es) | 2012-07-19 |
| US20070043027A1 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551997T1 (de) | Sulfonamid-derivate zur behandlung von diabetes | |
| EP1873144A4 (de) | Kondensierte heterocyclische verbindung | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| EA200600527A1 (ru) | Активирующее ppar соединение и содержащая его фармацевтическая композиция | |
| NO20083480L (no) | Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| ATE472531T1 (de) | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 | |
| WO2008155668A3 (en) | Heteroarylamide pyrimidone compounds | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
| PE20061054A1 (es) | Derivados de l- leucinamida como inhibidores de cisteinproteasas | |
| ATE455772T1 (de) | Alkinylarylcarbonsäureamide | |
| WO2008155669A3 (en) | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| NO20061614L (no) | Benzimidazolacetonitriler | |
| EP1818329A4 (de) | (s)-(-)-1-(4-fluorisochinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazinhydrochlorid- dihydrat | |
| CY1113042T1 (el) | Αντιμετωπιση μυϊασης | |
| DE602006003769D1 (de) | Verfahren zur herstellung von 4-amino-4'-demethyl-4-desoxypodophylotoxin | |
| EA200700767A1 (ru) | Способ получения пиразолов | |
| DE602004024170D1 (de) | Pyrrolidin-derivate als oxytocin antagonisten | |
| RU2014135323A (ru) | Соединение, способ получения соединения и способ очистки соединения | |
| AR068442A1 (es) | Inhibidores de la epoxido hidrolasa soluble | |
| MX2007005617A (es) | Derivados de vinilaminopirazol como pesticidas. | |
| TH98281A (th) | สารประกอบไซคลิกหลอม | |
| BR0316148A (pt) | Pirazolinocarboxanilidas substituìdas como composições praguicidas | |
| TH85588B (th) | สารไพแรโซโล พิริมิดีน |